EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: Tumor regression after reduction of immunosuppression - a case report

Diagnostic Pathology

Volumn 5, Issue 1, 2010, Pages

  Krenauer, Alexander ^a   Moll, Alexander ^a   Pönisch, Wolfram ^a   Schmitz, Nicole ^a   Niedobitek, Gerald ^b   Niederwieser, Dietger ^a   Aigner, Thomas ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNFALLKRANKENHAUS BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOTRANSPLANTATION; ARTICLE; B LYMPHOCYTE; BIOPSY; CASE REPORT; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS INFECTION; FATALITY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PATHOLOGY; STEM CELL TRANSPLANTATION; VIROLOGY; VIRUS ACTIVATION;

ADOLESCENT; B-LYMPHOCYTES; BIOPSY; CELL PROLIFERATION; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 77950445749     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-5-21     Document Type: Article

References (18)

1. Epstein MA, Achong BG, Barr YM. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet 1964, 1:702-703. 10.1016/S0140-6736(64)91524-7, 14107961.
2. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003, 31:145-155. 10.1038/sj.bmt.1703806, 12621474.
3. Hsieh WS, Lemas MV, Ambinder RF. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease. Transpl Infect Dis 1999, 1:204-212. 10.1034/j.1399-3062.1999.010308.x, 11428990.
4. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997, 14:8-14.
5. Niedobitek G, Young LS, Herbst H. Epstein-Barr virus infection and the pathogenesis of malignant lymphomas. Cancer Surveys 1997, 30:143-162.
6. Rowe M, Niedobitek G, Young LS. Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders. Springer Semin Immunopathol 1998, 20:389-403. 10.1007/BF00838051, 9870253.
7. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Hardesty RL. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1:583-587. 10.1016/S0140-6736(84)90994-2, 6142304.
8. Rickinson AB, Rowe M, Hart IJ, Yao QY, Henderson LE, Rabin H, Epstein MA. T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol 1984, 87:646-658. 10.1016/0008-8749(84)90032-7, 6088089.
9. Heslop HE, Savoldo B, Rooney CM. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol 2004, 17:401-413. 10.1016/j.beha.2004.05.007, 15498712.
10. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007, 25:587-617. 10.1146/annurev.immunol.25.022106.141553, 17378764.
11. Mentzer SJ, Perrine SP, Faller DV. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis 2001, 3:177-185. 10.1034/j.1399-3062.2001.003003177.x, 11493400.
12. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998, 66:1770-1779. 10.1097/00007890-199812270-00035, 9884275.
13. Salazar-Mather TP, Ishikawa R, Biron CA. NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection. J Immunol 1996, 157:3054-3064.
14. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, Atchison RW, Karrer F, Nalesnik MA, Starzl TE. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988, 45:719-727. 10.1097/00007890-198804000-00011, 2833828.
15. Davis JE, Moss DJ. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigens 2004, 63:285-292. 10.1111/j.0001-2815.2004.00227.x, 15009802.
16. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005, 104:1661-1667. 10.1002/cncr.21391, 16149091.
17. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005, 56:29-44. 10.1146/annurev.med.56.082103.104727, 15660500.
18. Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander AR, Bacher U. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008, 42:181-186. 10.1038/bmt.2008.150, 18516079.